For millions of people plagued by migraines, relief can feel like a far-off dream. But a new use for a popular class of weight-loss drugs may offer unexpected hope, without shedding a single pound.
Liraglutide, a medication originally used to treat obesity and diabetes, is now showing promise in a very different battle: reducing the number of migraine days. In a small but exciting new study, patients who suffered from frequent migraines experienced nearly half as many headache days after 12 weeks of daily liraglutide injections.
“Basically, we observed that patients saw their days with headache halved, which is huge,” said neurologist Simone Braca, who led the research at the University of Naples Federico II in Italy.
Liraglutide belongs to a group of medications called GLP-1 agonists, including more well-known names like Ozempic and Wegovy. These drugs mimic a natural hormone that regulates appetite and blood sugar. But scientists have recently discovered another surprising side effect: they reduce pressure inside the skull, a factor long linked to migraine pain.
Braca and his team suspected that lowering this pressure might provide a new way to prevent migraines. They enrolled 31 adults, mostly women, who had obesity and suffered migraines on around 20 days each month. After three months on liraglutide, that number dropped to about 11 days a month.
What are the results? Happier brains and far fewer pain-filled days. And get this, their weight barely changed, meaning the headache relief wasn’t just a result of weight loss. The drug itself seems to be playing a key role in calming those crippling headaches.
Unlike many clinical trials, this early-phase study did not include a placebo group, and both patients and doctors were aware of the drug being used. That means we’ll need more rigorous studies to confirm the findings. But the early signs are promising, and they could open new doors for people who haven’t responded well to current migraine medications.
Some patients don’t respond to CGRP blockers or other modern treatments. Braca noted, “What I would like to say to these patients is that research is going forward.”
Migraine is not “just a headache.” It’s a full-body disruption that affects over one billion people globally, often interfering with work, social life, and mental health. Any treatment that can cut those days in half, without adding more pills or side effects, deserves a closer look.
The study, recently published in Headache and presented at the European Academy of Neurology Congress in Finland, adds momentum to the growing conversation around GLP-1 drugs being more than just weight-loss tools.
The next steps will be larger clinical trials that include people of different weights and comparison groups to rule out placebo effects. If results stay strong, we could be looking at a new era of migraine care, one where the treatment already exists and is hiding in plain sight.
So, could the next big thing in migraine relief come from a weight-loss drug? The answer is: yes, and sooner than we think.
For more details, refer to this article published in Headache.
Copyright @smorescience. All rights reserved. Do not copy, cite, publish, or distribute this content without permission.
